ALPER MENGİ, BENGİ GÜL TÜRK, UGUR UYGUNOGLU
Turkish Journal of Physical Medicine and Rehabilitation - 2024;70(4):550-553
Subcutaneous botulinum toxin type A is recommended for neuropathic pain at the level of spinal cord injury. Herein, we present a 42-year-old female patient who presented to our outpatient clinic with neuropathic pain in the soles for eight years due to cervical long-segment myelitis. The patient had previously received various ineffective oral medications for the symptoms. Botulinum toxin type A was injected subcutaneously into bilateral soles. The patient was evaluated in the first, second, third, fourth, and sixth months after the injection. The daytime and nighttime Visual Analog Scale, Neuropathic Pain Questionnaire, Short Form-36, and Beck Depression Inventory scores improved during follow-up.
